Core Insights - Nordicus Partners Corporation is focused on supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market and has provided a corporate update on its subsidiaries and Nasdaq uplisting application [1] Subsidiary Developments - Orocidin is set to begin its first pilot efficacy study in Q3 2026 at the University of Copenhagen, contingent upon the completion of GMP for clinical use, with a pivotal 8-week toxicology study expected to be completed by April 2026 [2] - Bio-Convert anticipates the final GMP product to be completed by August 2026, with patient testing for its product QR-02 expected to start in Q3 2026 in Gothenburg, Sweden [3] - NoviThera is conducting a mouse study to assess the impact of varying doses of a pathogenic polypeptide on psoriasis development, with results and next milestones to be reported in approximately one month [4] Nasdaq Uplisting - Nordicus has applied to uplist its common shares from the OTCQB Market to the Nasdaq Capital Market, and the process is ongoing [5] Other Activities - The company is actively scouting the Nordic region for additional accelerator clients and potential high-growth acquisitions in the life sciences sector [6] Company Overview - Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies, specializing in corporate finance activities, business development, and facilitating acquisitions [7]